CTLA4 and cutaneous melanoma: It has shown extraordinary progress in patients with cutaneous melanoma, including PD-L1 and anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) checkpoint inhibitors (Boutros et al., 2016).